Advenio

What Advenio does

Advenio (legal entity Advenio Tecnosys Pvt. Ltd., previously known as ChironX) is an India-based healthcare AI company that builds AI-driven predictive diagnostic tools, anchored by its browser-based teleophthalmology platform Adven-i. Adven-i analyzes images from third-party Fundus Cameras using the company's proprietary AI algorithms, applying explainable AI, causal machine learning, computer vision, and advanced image processing to detect retinal abnormalities with self-reported accuracy above 94%. The platform runs in Chrome on standard laptops, desktops, and tablets without dedicated hardware installation, and the company offers a clinical validation page alongside the product.

The company sells to eye hospitals, ophthalmology clinics, diabetic care providers, and broader healthcare institutions through a usage-based SaaS model. Customers prepay for usage via Advenio's cPanel payment platform (cPanel.advenio.app or cPanel.advenio.dev), with refunds linked to actual usage. Distribution combines direct enterprise sales with demo-driven conversion (a free demo can be booked on the company website) and self-serve onboarding through its telemed.advenio.app platform. The Advenio Telemed System extends the offering into broader remote consultation and health record management.

Commercially, Advenio operates primarily within India and has built credibility through grants from BIRAC (SBIRI), Government of India, and the Bill and Melinda Gates Foundation, USA, alongside participation in accelerator and impact programs including Zone Startups India's empoWer, Unreasonable Group / Barclays, and Start Tel Aviv. The company is led by Mausumi Acharyya (PhD, ISI and University of Pennsylvania, ex-Siemens and GE) and a small leadership team including a Business Head, Sr. VP Product, and product marketing manager, with 11-50 employees and offices in Kolkata (headquarters) and Karnal.

Name

Advenio

Legal name

Advenio Tecnosys Pvt. Ltd.

Website

https://adveniotecnosys.tech

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

Advenio is an India-based healthcare AI company that builds Adven-i, a browser-based teleophthalmology platform using proprietary AI to detect retinal abnormalities from Fundus Camera images for healthcare providers and eye care institutions.

Ownership category

akta.pro rank

Product category

AI Teleophthalmology Software

akta.pro primary industry

Ophthalmology & Vision Telemedicine Platforms (HLALAGAL)

Keywords

• AI teleophthalmology
• Retinal disease screening
• Fundus image analysis
• Predictive diagnostics
• Medical image AI

Headquarters

HQ city

Chandigarh

HQ country

India

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. SaaS Subscription - Advenio Telemed System: Advenio operates on a SaaS (Software as a Service) model where customers are charged based on usage. Users must do prepaid recharge through Advenio's cPanel payment platform (cPanel.advenio.app or cPanel.advenio.dev). The system supports online payments through third-party payment gateways.
2. Usage-Based Recharge: Customers prepay for services through the cPanel platform and are charged per usage. Cancellation policy provides partial refunds: 100% refund before usage, remaining balance refunded after usage.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Advenio develops and sells an AI-driven teleophthalmology platform (Adven-i) that analyzes retinal images from third-party Fundus Cameras through a browser-based interface, using proprietary AI algorithms to detect retinal abnormalities with above 94% accuracy. It also offers the Advenio Telemed System, a SaaS telemedicine platform for remote consultations and health record management, sold on a prepaid, usage-based subscription to healthcare providers.

Product overview

Advenio offers an AI-driven healthcare diagnostic ecosystem consisting of two main products: the Adven-i platform, an AI-based teleophthalmology solution that works in browsers to detect retinal abnormalities using proprietary algorithms (achieving above 94% accuracy), and the Advenio Telemed System, a SaaS-based telemedicine platform for remote consultations and health record management. Both products integrate Fundus Camera hardware for data input and utilize the company's predictive diagnostic AI capabilities to serve healthcare providers and patients.

Differentiator

Problem solved

Functional benefit

Brands

• Adven-i: AI-based teleophthalmology platform for detecting retinal abnormalities with accuracy above 94%, operating through web browsers.
• Advenio TecnoSys

Products and services

• Adven-i AI-based teleophthalmology platform that runs in a web browser (Chrome on laptops, desktops, tablets) and analyzes images from third-party Fundus Cameras using Advenio's proprietary AI algorithms to detect retinal abnormalities with above 94% accuracy, targeted at eye hospitals, ophthalmology clinics, and diabetic care providers.
• Advenio Telemed System SaaS-based telemedicine platform that enables remote medical consultations and health record management for healthcare providers and their patients.

Quantifiable outcome

• Retinal abnormality detection accuracy above 94%

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature3 records

Partnerships

Three partnerships are on record, tiered core.

• Unreasonable Group (USA)coreGTM or Marketing Partner · 1 January 2018Founder Mausumi Acharyya is a Fellow of Unreasonable, USA. Advenio participated in Unreasonable Impact Asia Pacific 2018 in Hong Kong organized by Unreasonable Group and Barclays Bank. The founder also pitched at Royal Institute of Great Britain, UK at Impact World Forum Event 2018.
• Barclays BankcoreGTM or Marketing Partner · 1 January 2018Partnered with Barclays Bank through the Unreasonable Impact Asia Pacific programme, supporting companies creating jobs for the future. Featured in Livemint article highlighting Barclays and Unreasonable's support for impact ventures.
• Zone Startups IndiacoreGTM or Marketing Partner · 1 January 2016Advenio was selected for Zone Startups India's empoWer accelerator programme, supporting women entrepreneurs. The programme was covered in Times of India and YourStory, providing media exposure and startup ecosystem access.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Digital Diagnostics (IDx-DR): US-based pioneer of FDA-cleared autonomous AI for diabetic retinopathy detection (IDx-DR). Most direct comparable to Adven-i in product category, clinical use case, and B2B healthcare provider channel.
• Eyenuk: Developer of the EyeArt AI system, one of the most widely deployed FDA-cleared AI platforms for autonomous diabetic retinopathy screening. Directly competes with Adven-i in retinal disease AI screening for healthcare providers.
• Remidio Innovative Solutions: India-based ophthalmic device and AI-screening company that combines portable fundus cameras with AI-based DR screening. Closest India-headquartered peer to Advenio with overlapping teleophthalmology use cases.
• Forus Health: Bengaluru-based ophthalmic-device company (3nethra series) that has expanded into AI-driven retinal screening for DR and other conditions. Competes head-to-head with Advenio in Indian eye-care screening deployments.

Emerging players

• Aravind Eye Hospital (Eye-PACS / AI initiatives): Large Indian hospital network developing in-house and partnered AI tools for teleophthalmology and population-scale DR screening. Comparable as both a potential customer and a deployer of competing AI screening workflows in India.
• VoxelCloud: AI medical imaging company with retinal/diabetic-retinopathy screening among its diagnostics portfolio. Comparable as a peer-stage AI-healthcare startup targeting similar disease-screening workflows.

Broad incumbents

• Google Health (Verily / retinal AI): Has published and piloted AI models for retinal disease screening (including DR) and is a broad incumbent with vastly larger R&D and distribution resources. Represents the dominant strategic threat in the AI-ophthalmology category.
• Topcon Healthcare: Global ophthalmic equipment vendor expanding into AI-driven screening and disease detection via its Harmony/Imagenet platforms. Comparable as a vertically integrated fundus-camera-plus-AI incumbent in the same screening workflow.
• ZEISS Medical Technology: Major ophthalmic device and diagnostics company offering fundus imaging plus integrated AI screening workflows. Competes with Advenio at the procurement layer for eye hospitals and screening programs.
• Optos (Nikon Healthcare): Specialist in ultra-widefield retinal imaging whose devices and AI image-management software are commonly used in DR and AMD screening pipelines. Adjacent incumbent to Advenio in the fundus-imaging-and-screening ecosystem.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/advenio-tecnosys-private-limited

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Advenio